Non-medullary thyroid carcinoma (NMTC) refers to malignant tumors originating from follicular cells of the thyroid gland, including papillary, follicular and undifferentiated carcinomas, which account for the majority of thyroid cancers, whereas medullary thyroid carcinoma originates from C cells of the thyroid gland. Previously, it was recognized that thyroid cancer with genetic predisposition was mainly familial medullary carcinoma, while non-medullary carcinoma was generally sporadic. It is now believed that familial thyroid cancer can be divided into familial medullary thyroid carcinoma,, and familial non-medullary thyroid carcinoma. Currently, Thomas. has proposed a reference standard for the diagnosis of familial papillary thyroid cancer: Primary criteria 1. 2 or more patients with papillary thyroid cancer in first-degree relatives; 2. 1 patient with papillary thyroid cancer and 3 patients with nodular goiter or offspring nodular goiter in first-degree relatives; Secondary criteria 3. Age of onset less than 33 years; 4. Multiple 4, multiple carcinomas or bilateral lobe papillary thyroid cancer; 5, T4 lesions; 6, lymph node metastases or distant metastases; 7, multiple adolescent thyroid cancer patients in the family. The diagnosis of familial papillary thyroid cancer was made by satisfying 2 major conditions or 1 major condition and 3 minor conditions under the exclusion of familial tumor syndromes such as Cardner syndrome. Analysis From January 2009 to January 2013, the proportion of bilobar carcinoma was as high as 51.4%, the proportion of multiple carcinoma foci was as high as 68.6%, and the incidence of lymph node metastasis in the central region was as high as 62.9%, and the proportion of bilobar onset or lymph node metastasis or infiltration of the peritoneum was as high as 94.3% in 35 cases of FTC in this paper admitted by me in the Department of Thyroid Surgery of our hospital. After comparing the clinical characteristics of 35 cases of FTC with 221 cases of STC in our thyroid surgery department during the same period, it was concluded that the incidence of bilobar carcinoma and the proportion of lymph node metastasis in the central region were significantly higher in FTC than in STC, and the difference was statistically significant (P<0.05< span="">), while the rest of the differences were not statistically significant (P>0.05), and it was also confirmed in the literature that the proportion of bilobar carcinoma and lymph node metastasis in familial papillary carcinoma was high. carcinoma and high proportion of lymph node metastasis. Therefore, it is recommended that all FTCs should be treated with a thorough initial surgery: radical thyroid cancer resection (total bilobectomy + lymph node dissection in the central region) with additional prophylactic lymph node dissection in the cervical region if necessary, postoperative I131 therapy and endocrine suppression therapy, and lifelong follow-up. On the one hand, total excision is beneficial to I131 therapy, and on the other hand, Tg becomes a more sensitive indicator at the time of review. FNMTC usually occurs in first and second degree relatives of patients, and the prevalence of first degree relatives is 5-8 times higher than that of the general population. If two or more family members have thyroid cancer, then all first- and second-degree family members should be screened with nuchal ultrasound; if the patient has multiple lesions or nodules, then first- and second-degree family members should also be screened. If first- and second-degree family members have nodules, surgery should be relaxed and followed by prophylactic radioiodine therapy. In terms of familial thyroid cancer genes, the RET proto-oncogene is currently recognized as the main cause of FMTC, and studies have shown that over 90% of thyroid cancers have Ret gene rearrangements, which are most closely related to papillary thyroid cancer, while Ret gene mutations are most closely related to medullary thyroid cancer, suggesting that Ret proto-oncogene variants may have specific significance for the diagnosis of papillary thyroid cancer and medullary thyroid cancer. The specific significance of Ret proto-oncogene variants in the diagnosis of papillary thyroid cancer and medullary thyroid cancer. In conclusion, we should properly recognize and actively screen for FTC so that the disease can be detected early and treated appropriately to improve the quality of life of patients and their families.